These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

103 related articles for article (PubMed ID: 15283466)

  • 1. Recombinant adenoviral vector containing tumor-specific L-plastin promoter fused to cytosine deaminase gene as a transcription unit: generation and functional test.
    Chung I; Deisseroth AB
    Arch Pharm Res; 2004 Jun; 27(6):633-9. PubMed ID: 15283466
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cytotoxic effect of replication-competent adenoviral vectors carrying L-plastin promoter regulated E1A and cytosine deaminase genes in cancers of the breast, ovary and colon.
    Akbulut H; Zhang L; Tang Y; Deisseroth A
    Cancer Gene Ther; 2003 May; 10(5):388-95. PubMed ID: 12719708
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cytotoxic effect of a replication-incompetent adenoviral vector with cytosine deaminase gene driven by L-plastin promoter in hepatocellular carcinoma cells.
    Jung K; Kim S; Lee K; Kim C; Chung I
    Arch Pharm Res; 2007 Jun; 30(6):770-7. PubMed ID: 17679557
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The use of the L-plastin promoter for adenoviral-mediated, tumor-specific gene expression in ovarian and bladder cancer cell lines.
    Peng XY; Won JH; Rutherford T; Fujii T; Zelterman D; Pizzorno G; Sapi E; Leavitt J; Kacinski B; Crystal R; Schwartz P; Deisseroth A
    Cancer Res; 2001 Jun; 61(11):4405-13. PubMed ID: 11389068
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Use of L-plastin promoter to develop an adenoviral system that confers transgene expression in ovarian cancer cells but not in normal mesothelial cells.
    Chung I; Schwartz PE; Crystal RG; Pizzorno G; Leavitt J; Deisseroth AB
    Cancer Gene Ther; 1999; 6(2):99-106. PubMed ID: 10195877
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cytosine deaminase adenoviral vector and 5-fluorocytosine selectively reduce breast cancer cells 1 million-fold when they contaminate hematopoietic cells: a potential purging method for autologous transplantation.
    Garcia-Sanchez F; Pizzorno G; Fu SQ; Nanakorn T; Krause DS; Liang J; Adams E; Leffert JJ; Yin LH; Cooperberg MR; Hanania E; Wang WL; Won JH; Peng XY; Cote R; Brown R; Burtness B; Giles R; Crystal R; Deisseroth AB
    Blood; 1998 Jul; 92(2):672-82. PubMed ID: 9657770
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Engineering conditionally replication-competent adenoviral vectors carrying the cytosine deaminase gene increases the infectivity and therapeutic effect for breast cancer gene therapy.
    Liu Y; Ye T; Maynard J; Akbulut H; Deisseroth A
    Cancer Gene Ther; 2006 Apr; 13(4):346-56. PubMed ID: 16179927
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Vector targeting makes 5-fluorouracil chemotherapy less toxic and more effective in animal models of epithelial neoplasms.
    Akbulut H; Tang Y; Maynard J; Zhang L; Pizzorno G; Deisseroth A
    Clin Cancer Res; 2004 Nov; 10(22):7738-46. PubMed ID: 15570008
    [TBL] [Abstract][Full Text] [Related]  

  • 9. In vivo adenovirus-mediated gene transfer of the Escherichia coli cytosine deaminase gene to human colon carcinoma-derived tumors induces chemosensitivity to 5-fluorocytosine.
    Hirschowitz EA; Ohwada A; Pascal WR; Russi TJ; Crystal RG
    Hum Gene Ther; 1995 Aug; 6(8):1055-63. PubMed ID: 7578418
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Regional 'pro-drug' gene therapy: intravenous administration of an adenoviral vector expressing the E. coli cytosine deaminase gene and systemic administration of 5-fluorocytosine suppresses growth of hepatic metastasis of colon carcinoma.
    Topf N; Worgall S; Hackett NR; Crystal RG
    Gene Ther; 1998 Apr; 5(4):507-13. PubMed ID: 9614575
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Low-dose etoposide enhances telomerase-dependent adenovirus-mediated cytosine deaminase gene therapy through augmentation of adenoviral infection and transgene expression in a syngeneic bladder tumor model.
    Shieh GS; Shiau AL; Yo YT; Lin PR; Chang CC; Tzai TS; Wu CL
    Cancer Res; 2006 Oct; 66(20):9957-66. PubMed ID: 17047058
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Specific CEA-producing colorectal carcinoma cell killing with recombinant adenoviral vector containing cytosine deaminase gene.
    Shen LZ; Wu WX; Xu DH; Zheng ZC; Liu XY; Ding Q; Hua YB; Yao K
    World J Gastroenterol; 2002 Apr; 8(2):270-5. PubMed ID: 11925606
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [In vitro treatment of ovarian cancer cells with cytosine deaminase-thymidine kinase fusion disuicide gene therapy system under the control of human telomerase reverse transcriptase gene promoter].
    Kong BH; Song Y; Ma DX; Qu X; Jiang S
    Zhonghua Fu Chan Ke Za Zhi; 2004 Jun; 39(6):390-5. PubMed ID: 15312323
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Gene therapy of adenovirus mediated CD ::upp/5-FC directed by GSTP1 promoter in cisplatin-resistant ovarian cancer.
    Wang Z; Cai L; Wang H
    Gynecol Oncol; 2005 Mar; 96(3):643-50. PubMed ID: 15721406
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In vivo adenoviral-mediated gene transfer in the treatment of pancreatic cancer.
    Evoy D; Hirschowitz EA; Naama HA; Li XK; Crystal RG; Daly JM; Lieberman MD
    J Surg Res; 1997 Apr; 69(1):226-31. PubMed ID: 9202675
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A Bicistronic Adenoviral Vector Carrying Cytosine Deaminase and Granulocyte-Macrophage Colony-Stimulating Factor Increases the Therapeutic Efficacy of Cancer Gene Therapy.
    Akbulut H; Coleri A; Sahin G; Tang Y; Icli F
    Hum Gene Ther; 2019 Aug; 30(8):999-1007. PubMed ID: 30892086
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Enzyme/prodrug gene therapy for human colon cancer cells using adenovirus-mediated transfer of the Escherichia coli cytosine deaminase gene driven by a CAG promoter associated with 5-fluorocytosine administration.
    Koyama F; Sawada H; Fujii H; Hirao T; Ueno M; Hamada H; Nakano H
    J Exp Clin Cancer Res; 2000 Mar; 19(1):75-80. PubMed ID: 10840940
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Adenoviral-mediated imaging of gene transfer using a somatostatin receptor-cytosine deaminase fusion protein.
    Lears KA; Parry JJ; Andrews R; Nguyen K; Wadas TJ; Rogers BE
    Cancer Gene Ther; 2015 Mar; 22(4):215-21. PubMed ID: 25837665
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Enhanced EJ Cell Killing of (125)I Radiation by Combining with Cytosine Deaminase Gene Therapy Regulated by Synthetic Radio-Responsive Promoter.
    Li L; Zhang CL; Kang L; Wang RF; Yan P; Zhao Q; Yin L; Guo FQ
    Cancer Biother Radiopharm; 2015 Oct; 30(8):342-8. PubMed ID: 26382009
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Gene therapy for ovarian cancer using adenovirus-mediated transfer of cytosine deaminase gene and uracil phosphoribosyltransferase gene directed by MDR1 promoter.
    Lu S; Wang X; Xiao L; Cai L; Zhang Y; Wang H; Wang Z
    Cancer Biol Ther; 2007 Mar; 6(3):397-404. PubMed ID: 17471022
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.